Table 3. Validation of the MBCSIM model in 108 ER-positive breast cancer patients for a follow-up period of 5 years.
| Validation database | Simulation (mean±s.d.) | |
|---|---|---|
|
Initial imaging tests | ||
| 116 | 104.0±6.5 | |
| BS and X-bone | 53 | 52.2±3.8 |
| MRI bone | 8 | 15.3±2.2 |
| FDG-PET/CT | 3 | 1.2±0.3 |
| X-ray lung | 31 | 16.9±0.8 |
| CT lung/liver | 7 | 2.0±0.4 |
| Ultrasound liver | 7 | 7.0±0.3 |
| MRI liver | 0 | 0.2±0.1 |
| MRI brain | 7 | 9.2±2.5 |
| FES-PET/CT | 0 | 0.0±0.0 |
|
Staging tests | ||
| 13 | 17.9±1.3 | |
| CT lung+CT liver | 5 | 11.3±1.0 |
| BS+CT lung+CT liver | 8 | 6.6±0.9 |
|
Biopsy tests | ||
| 18 | 20.3±1.5 | |
| Bone | 6 | 7.4±1.0 |
| Lung | 10 | 5.6±0.5 |
| Liver | 0 | 3.3±0.2 |
| Brain | 2 | 4.0±1.0 |
|
MBCs found | ||
| 14 | 10.2±1.0 | |
| Bone | 8 | 3.7±0.6 |
| Lung | 3 | 2.7±0.3 |
| Liver | 2 | 2.6±0.2 |
| Brain | 1 | 1.2±0.3 |
Abbreviations: BS, bone scan; CT=computed tomography; ER=oestrogen receptor; FDG=2-[18F]fluoro-2-deoxy-D-glucose; FES=16α-[18F]fluoro-17β-oestradiol; MBC=metastatic breast cancer; MBCSIM, metastatic breast cancer simulation; MRI=magnetic resonance imaging; PET=positron emission tomography.